Literature DB >> 14691186

Oncofetal fibronectin in diabetic retinopathy.

Zia A Khan1, Mark Cukiernik, John R Gonder, Subrata Chakrabarti.   

Abstract

PURPOSE: Imbalance between extracellular matrix protein synthesis and degradation is a key feature of diabetic retinopathy. Fibronectin, a predominant constituent of the extracellular matrix, has been shown to undergo alternative splicing to produce embryonic isoforms in various pathologic conditions, such as fibrotic diseases and tumorigenesis. Two such isoforms, oncofetal fibronectin variants that are characterized by the inclusion of the oncofetal domains A and B, were the focus of the present study.
METHODS: The expression of oncofetal fibronectin variants was determined in human vitreous samples obtained from patients undergoing vitrectomy for proliferative diabetic retinopathy and nondiabetes-associated ocular conditions such as macular hole. In addition, an animal model of chronic diabetes and cultured endothelial cells was used to elucidate the mechanistic basis for this aberrant expression of oncofetal fibronectin.
RESULTS: Expression of fibronectin containing the oncofetal domain B was upregulated in the vitreous of patients with diabetic retinopathy.
CONCLUSIONS: Use of a well-established animal model of chronic diabetic complications and cultured endothelial cells showed that diabetes-induced upregulation of oncofetal fibronectin is, in part, dependent on hyperglycemia-induced transforming growth factor-beta1 and endothelin-1. Furthermore, the data suggest that oncofetal fibronectin is involved in endothelial cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14691186     DOI: 10.1167/iovs.03-0540

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Conditional knockout of fibronectin abrogates mouse mammary gland lobuloalveolar differentiation.

Authors:  Keyi Liu; Le Cheng; Andrea Flesken-Nikitin; Lynn Huang; Alexander Y Nikitin; Bendicht U Pauli
Journal:  Dev Biol       Date:  2010-08-10       Impact factor: 3.582

2.  Glucose-induced Akt1 activation mediates fibronectin synthesis in endothelial cells.

Authors:  X Xin; Z A Khan; S Chen; S Chakrabarti
Journal:  Diabetologia       Date:  2005-09-29       Impact factor: 10.122

3.  Glucose-induced up-regulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction.

Authors:  H Farhangkhoee; Z A Khan; Y Barbin; S Chakrabarti
Journal:  Diabetologia       Date:  2005-05-25       Impact factor: 10.122

4.  Tenascin-C produced by oxidized LDL-stimulated macrophages increases foam cell formation through Toll-like receptor-4.

Authors:  Rui Liu; Yong He; Bo Li; Jun Liu; Yingang Ren; Wei Han; Xing Wang; Lihua Zhang
Journal:  Mol Cells       Date:  2012-06-12       Impact factor: 5.034

5.  ERK5 Contributes to VEGF Alteration in Diabetic Retinopathy.

Authors:  Yuexiu Wu; Yufeng Zuo; Rana Chakrabarti; Biao Feng; Shali Chen; Subrata Chakrabarti
Journal:  J Ophthalmol       Date:  2010-06-30       Impact factor: 1.909

6.  Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes.

Authors:  Arjun Jain; Shali Chen; Hannah Yong; Subrata Chakrabarti
Journal:  J Diabetes Metab Disord       Date:  2018-10-18

7.  Endothelin-1 role in human eye: a review.

Authors:  Serena Salvatore; Enzo Maria Vingolo
Journal:  J Ophthalmol       Date:  2011-03-03       Impact factor: 1.909

8.  Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose.

Authors:  Emily Keats; Zia A Khan
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

Review 9.  Proinsulin C-peptide: friend or foe in the development of diabetes-associated complications?

Authors:  Lina Nordquist; M Johansson
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Cellular signaling and potential new treatment targets in diabetic retinopathy.

Authors:  Zia A Khan; Subrata Chakrabarti
Journal:  Exp Diabetes Res       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.